Clinical trial · Observational
Optimization of Management for Sporadic Bilateral Renal Cell Carcinoma
Optimization of Management for Sporadic Bilateral Renal Cell Carcinoma: a Population-based Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Sporadic bilateral renal cell carcinoma (BRCC) is a rare situation of RCC. The treatment for BRCC is controversial and there is a lack of authoritative guidelines about the management of BRCC. The goal of this cohort study is to identify prognostic factors, construct predictive nomograms, and optimize management for sporadic BRCC patients. The main questions it aims to answer are: What are the factors influencing the prognosis of BRCC patients? What's the appropriate treatment for BRCC patients? Researchers will analysis the prognostic factors and compare the prognosis of BRCC patients receiving different treatments.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Kidney Cancer | Malignant Kidney Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Surgery treatment or local tumor destruction. | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Synchronous BRCC patients
- description
- Synchronous BRCC is defined as the second primary RCC emerges within 6 months from the diagnosis of the first primary RCC.
- interventionNames
- Procedure: Surgery treatment or local tumor destruction.
- label
- Metachronous BRCC patients
- description
- Metachronous BRCC develops beyond 6 months from the diagnosis of the first primary RCC.
- interventionNames
- Procedure: Surgery treatment or local tumor destruction.
Primary outcomes (1)
- measure
- Overall survival (OS)
- timeFrame
- From date of diagnosis of the second primary RCC until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 20 years.
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years. * Clinical diagnosis of localized BRCC (M0) from 2000 to 2020. * Active follow-up. * Complete clinicopathological information. Exclusion Criteria: * Diagnosed by autopsy or death certificate only. * Tending to suffer from hereditary RCC, including those complicating with pancreatic neuroendocrine tumor (pNET) or hemangioblastoma. * Unavailable key information.
References
Publications (1)
- DERIVEDDeng R, Qiu J, Shang J, Yu C, Tian P, Zhao Z, Cai L, Zhou J, Gong K. The long-term survival outcome of sporadic bilateral renal cell carcinoma and optimization of surgical treatment: a large-scale population-based cohort study. Clin Exp Med. 2024 Dec 21;25(1):20. doi: 10.1007/s10238-024-01535-5. PMID 39708253